Skip Navigation
Menu
ACP Journal Club |21 October 2014

Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults

Fainareti N. Zervou, MD; Ioannis M. Zacharioudakis, MD; Eleftherios Mylonakis, MD, PhD

Article, Author, and Disclosure Information
FULL TEXT
Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169-79. 24897082

Hospitalists:

Infectious Disease:

In adults with acute bacterial skin and skin-structure infection (SSSI), is weekly dalbavancin noninferior to daily vancomycin?
2 replicate, randomized, controlled, noninferiority trials (DISCOVER-1 and DISCOVER-2). ClinicalTrials.gov NCT01339091 and NCT01431339.
Concealed.*
Blinded* (patients, clinicians, {data collectors, outcome assessors, data analysts, and safety committee}†).
14 days.
140 investigative sites in the USA, Canada, Europe, South Africa, and Asia.
573 adults in DISCOVER-1 (mean age 49 y, 60% men) and 739 adults in DISCOVER-2 (mean age 50 y, 57% men) who had acute bacterial SSSI (cellulitis, major abscess, or wound infection, with ≥ 75 cm2 of erythema) and would probably need ≥ 3 days of IV antibiotics; had ≥ 1 systemic sign of infection (temperature > 38°C, white cell count > 12 000 cells/mm3, or > 10% band forms on white cell differential count) in the past 24 hours; and ≥ 2 of purulent drainage or discharge, fluctuance, heat or localized warmth, tenderness on palpation, and swelling or induration in addition to erythema. Exclusion criterion was antibiotic therapy in the past 14 days.
FULL TEXT
PDF
Not Available
Citations
Citation

Zervou FN, Zacharioudakis IM, Mylonakis E. Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults. Ann Intern Med. 2014;161:JC9. doi: 10.7326/0003-4819-161-8-201410210-02009

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2014;161(8):JC9.

DOI: 10.7326/0003-4819-161-8-201410210-02009

2 Citations

Related Articles
Annals for Educators - 1 November 2016
Annals of Internal Medicine; 165 (9): ED9
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence
Annals of Internal Medicine; 165 (2): JC4
Review: Fidaxomicin is better than vancomycin for Clostridium difficile recurrence
Annals of Internal Medicine; 156 (8): JC4-9
Comparative Effectiveness of Clostridium difficile Treatments: A Systematic Review
Annals of Internal Medicine; 155 (12): 839-847
View MoreView Less

Journal Club
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence
Annals of Internal Medicine; 165 (2): JC4
Review: Fidaxomicin is better than vancomycin for Clostridium difficile recurrence
Annals of Internal Medicine; 156 (8): JC4-9
View MoreView Less

Related Topics
Hospital Medicine

Hospital Medicine.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×